argenx SE (LON:0QW0)

London flag London · Delayed Price · Currency is GBP · Price in EUR
786.27
-2.93 (-0.37%)
At close: Nov 28, 2025
34.58%
Market Cap41.94B
Revenue (ttm)2.74B
Net Income (ttm)1.14B
Shares Outn/a
EPS (ttm)17.31
PE Ratio36.77
Forward PE31.50
Dividendn/a
Ex-Dividend Daten/a
Volume49,030
Average Volume17,212
Open791.50
Previous Close789.20
Day's Range782.40 - 793.60
52-Week Range352.20 - 809.80
Beta-0.11
RSI63.78
Earnings DateFeb 26, 2026

About argenx SE

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 1,599
Stock Exchange London Stock Exchange
Ticker Symbol 0QW0
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.